NOT-AG-18-059: Notice of Changes to Award Information for RFA-AG-19-026 "Development of Personalized In Vitro Assays to Quantitatively Assess Age-related Changes in Cellular Resiliencies to Physiologic Stressors (R41/R42 Clinical Trial Not Allowed)"

Notice of Changes to Award Information for RFA-AG-19-026 "Development of Personalized In Vitro Assays to Quantitatively Assess Age-related Changes in Cellular Resiliencies to Physiologic Stressors (R41/R42 Clinical Trial Not Allowed)"

Notice Number: NOT-AG-18-059

Key Dates
Release Date: January 4, 2019

Related Announcements
RFA-AG-19-026

Issued by
National Institute on Aging (NIA)

Purpose

The purpose of this Notice is to amend the application types allowed and award budget for RFA-AG-19-026 "Development of Personalized In Vitro Assays to Quantitatively Assess Age-related Changes in Cellular Resiliencies to Physiologic Stressors (R41/R42 Clinical Trial Not Allowed)".

Part 2, Section II, Award Information

Application Types Allowed

Currently reads:

New (Phase I, Fast-Track)
New (Phase II SBIR Direct Phase II Only)

The OER Glossary and the SF424 (R&R) SBIR/STTR Application Guide provide details on these application types.

Modified to read:

New (Phase I, Fast-Track)

The OER Glossary and the SF424 (R&R) SBIR/STTR Application Guide provide details on these application types.

Award Budget

Currently reads:

Budgets up to $225,000 direct costs per year for Phase I and up to $750,000 direct costs per year for Phase II may be requested.

Modified to read:

Budgets up to $300,000 total costs for Phase I and up to $1,000,000 total costs per year for Phase II may be requested with appropriate justification.

All other aspects of this FOA remain the same.

Inquiries

Please direct all inquiries to:

Todd Haim, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-480-7867
Email: [email protected]